July 1948


Author Affiliations


From the Diabetic Service of Wesley Memorial Hospital and the Northwestern University Medical School, Department of Medicine.

Arch Intern Med (Chic). 1948;82(1):54-62. doi:10.1001/archinte.1948.00220250064003

THERE has been constant and increasing interest in the time action of modified insulins in the search for an ideal preparation capable of providing good control for the greatest number of diabetic patients by a single daily injection. The introduction of protamine insulin by Hagedorn1 in 1936 was a major contribution, and in a large number of cases the diabetes is satisfactorily controlled with single daily injections of protamine zinc insulin. However, it is evident that its time action is too prolonged for ideal purposes. Postprandial glycosuria and nocturnal reactions occur in many patients, particularly those with severe grades of diabetes. The need for an insulin with activity intermediate between that of regular insulin and that of protamine zinc insulin led to the development of globin insulin with zinc in 1939 by Reiner, Searle and Lang.2 This product has also been referred to as globin zinc insulin and

First Page Preview View Large
First page PDF preview
First page PDF preview